Chondrocyte Cells Guide | Akira Biotech

Overview

Articular chondrocytes differentiated from UCT-WJ-MSCs; producing type II collagen and aggrecan for cartilage matrix regeneration and joint repair

Related: Stem Cells Overview • Chondrocyte Exosomes

FOR RESEARCH USE AND INTERNATIONAL USE ONLY

Specs	Details
Source	Derived from P2 UCT-WJ-MSCs via chondrogenic pellet culture
Differentiation Protocol	TGF-β3 BMP-6 dexamethasone in serum-free chondrogenic medium
Cryopreservation	DMSO-free, glucose-based
Post-Thaw Viability	>98%
Storage	−80 °C long-term; −196 °C LN2 vapor phase for extended storage
Identity Markers	Type II Collagen⁺, Aggrecan⁺, SOX9⁺, COL2A1⁺, CD44⁺
Release Criteria	Alcian Blue staining confirms sulfated proteoglycan production prior to release.
Immunogenicity	HLA-DR⁻ (retained from UCT-WJ-MSC origin); immune-privileged for allogeneic intra-articular delivery without immunosuppression
Passage Limit	≤P2 from UCT-WJ-MSC
Manufacturing	cGMP, animal-product-free

Clinical Overview

Articular cartilage has minimal intrinsic healing capacity due to avascularity and limited progenitor cell content. Akira Chondrocytes derived from UCT-WJ-MSCs exhibit enhanced proliferative and matrix-producing capacity compared to adult chondrocytes, with lower dedifferentiation risk under in vitro expansion. These cells restore cartilage matrix integrity through both direct ECM deposition and paracrine modulation of joint inflammation. Delivered intra-articularly (with or without scaffold), they engage host chondrocytes via exosomal miRNAs (SOX9, miR-140) that suppress catabolism and promote anabolism. A 2024 systematic review of WJ-MSC clinical trials specifically for KOA (n=97 patients, 6 studies) confirmed significant functional improvement with no serious adverse events — providing the best available clinical evidence for this cell class.^[1]

A comparative spheroid-culture study found Wharton's-jelly-derived MSCs produce comparatively lower glycosaminoglycan (GAG) content than adipose-tissue-derived MSCs — so while UCT-derived chondrocytes are expected to retain greater proliferative capacity and lower dedifferentiation risk than adult primary chondrocytes (drawn from WJ-MSCs' generally high proliferative capacity, not a head-to-head study of this specific product), a categorical GAG-production advantage over adult-source chondrocytes is not independently confirmed.^[2]

Process

Mechanism of Action

Direct ECM Production: SOX9+ chondrocytes synthesize type II collagen fibrils and aggrecan proteoglycans — the primary structural components of articular cartilage.^[3] This matrix deposition restores mechanical load-bearing and joint lubrication function. Akira Chondrocytes are Collagen X negative, confirming a non-hypertrophic, stable articular phenotype rather than the transient growth-plate cartilage phenotype that undergoes vascular invasion and ossification.

Inflammation Suppression: MMP expression (MMP-13, MMP-3, ADAMTS-5) in the joint space is reduced via IL-10 and TGF-β secretion and miR-140 transfer in exosomes — slowing cartilage catabolism in osteoarthritis.^[4]^[5] A 2025 study of macrophage-polarization-targeted nanoparticle delivery in a rat rheumatoid arthritis model further supports the IL-10/TGF-β3-driven M2 polarization mechanism underlying this anti-catabolic effect.^[6]

Anabolic Signaling: IGF-1 and FGF-2 secreted by Akira Chondrocytes activate chondrocyte proliferation pathways and upregulate collagen II and aggrecan gene expression in neighboring host cartilage.^[7] In articular chondrocyte and progenitor contexts, FGF-2 drives expansion of the chondrocyte progenitor pool and anabolic signaling — distinct from growth-plate FGFR3 signaling, which is anti-proliferative.^[8]

Scaffold Compatibility: Akira Chondrocytes adhere to hyaluronic acid, fibrin, collagen, and bioprinted scaffolds, enabling cartilage tissue engineering constructs for focal defect repair, meniscal fibrocartilage augmentation (demonstrated in sheep models),^[9] and intervertebral disc nucleus pulposus replacement (demonstrated in vitro).^[10] These are investigational, preclinical-stage applications extending beyond simple cell injection.^[11]

Reduced Dedifferentiation Risk: UCT-derived chondrocytes are intended to offer enhanced proliferative and matrix-producing capacity relative to adult primary chondrocytes, with lower dedifferentiation risk — drawn from WJ-MSCs' generally high proliferative capacity and adult chondrocytes' well-documented dedifferentiation tendency in expanded culture, rather than a head-to-head comparative study of this specific product.

Biomarkers

Key Biomarkers & Molecular Cargo

Marker / Molecule	Functional Role
SOX9	Master chondrogenic transcription factor; drives COL2A1, ACAN expression
Type II Collagen (COL2A1)	Primary structural cartilage protein; tensile strength and matrix integrity
Aggrecan (ACAN)	Sulfated proteoglycan; compressive load bearing, water retention
miR-140	Cartilage-specific miRNA; suppresses MMP-13, ADAMTS-5 catabolism
TGF-β3 / IGF-1	Anabolic growth factors for matrix production and chondrocyte survival
CD44	Hyaluronate receptor; mediates chondrocyte adhesion to ECM and scaffold
IL-10 / IL-1Ra	Anti-inflammatory cytokines suppressing synovial inflammation in OA

Applications

Potential Applications

Knee Osteoarthritis (Grades I–IV) — intra-articular injection, chondrogenic regeneration
Focal Articular Cartilage Defects — autologous chondrocyte implantation analogue
Rheumatoid Arthritis Joint Damage — matrix restoration immunomodulation
Intervertebral Disc Degeneration — nucleus pulposus regeneration (disc scaffold)
Meniscal Tears & Degeneration — meniscal fibrocartilage repair
Patellofemoral Chondromalacia — patellar cartilage restoration
Sports-related Cartilage Injuries — focal defect repair for athletes
Post-traumatic Articular Damage — post-fracture cartilage healing

These are experimental use cases, provided as a scientific reference for researchers. Except where noted, they did not use Akira Biotech materials, and results may not be reproducible with ours. Akira Biotech supplies laboratory reagents for research use only. Our products are NOT approved by FDA or any regulatory authority and are not for use in or on humans.

Evidence

Clinical & Preclinical Evidence

The 2024 systematic review of WJ-MSC intra-articular injections for KOA (n=97 patients, 134 knees, 6 studies, follow-up 3–48 months) showed statistically significant improvements in VAS pain (mean reduction 3.2 points), WOMAC total score, KOOS, and IKDC — with no serious adverse events across all studies. Multiple-injection protocols produced superior outcomes over single injections.^[1]

A 2023 systematic review and meta-analysis (Frontiers in Endocrinology) of MSC therapies for OA across multiple RCTs confirmed consistent pain relief and functional improvement, with early MRI evidence of cartilage volume preservation in treated joints. The review endorsed allogeneic UCT-derived MSCs as among the best-characterized sources for joint therapy.^[12]

CARTISTEM® (hUCB-MSC product) Phase III pivotal trial using umbilical cord blood-derived MSCs in knee cartilage defects is underway, targeting superiority over surgical debridement at 2-year follow-up — establishing regulatory precedent for UCT-derived chondrocyte-lineage therapy.^[13]

In preclinical models of full-thickness cartilage defects, UCT-MSC-derived chondrocytes delivered in fibrin glue resulted in histological scores (ICRS score) of 8.4/12 at 12 weeks vs 3.1/12 in untreated defects — demonstrating substantial but not yet complete regeneration consistent with early-stage repair. COL2A1 expression was 85% of normal articular cartilage by immunohistochemistry.

A Phase II RCT of allogeneic adipose-MSC intra-articular injection confirmed cartilage regeneration on MRI with reduction of IL-1β and TNF-α in synovial fluid — mechanistically mirroring the expected outcome of Akira Chondrocyte delivery.^[14]

Chondrocyte Cells